Parkinson’s Disease and Related Disorders

Front Matter....Pages I-X
Melvin Yahr (1917–2004). An appreciation....Pages 1-4
Melvin D. Yahr, 1917–2004. A personal recollection....Pages 5-7
The discovery of dopamine deficiency in the parkinsonian brain....Pages 9-15
Synchronizing activity of basal ganglia and pathophysiology of Parkinson’s disease....Pages 17-20
Basal ganglia discharge abnormalities in Parkinson’s disease....Pages 21-25
Bad oscillations in Parkinson’s disease....Pages 27-30
Cortical muscle coupling in Parkinson’s disease (PD) bradykinesia....Pages 31-40
GDNF as a candidate striatal target-derived neurotrophic factor for the development of substantia nigra dopamine neurons....Pages 41-45
The engrailed transcription factors and the mesencephalic dopaminergic neurons....Pages 47-55
The role of Pitx3 in survival of midbrain dopaminergic neurons....Pages 57-60
Genetic analysis of dopaminergic system development in zebrafish....Pages 61-66
Striatal plasticity in parkinsonism: dystrophic changes in medium spiny neurons and progression in Parkinson’s disease....Pages 67-70
The nigrostriatal DA pathway and Parkinson’s disease....Pages 71-83
Relationship between axonal collateralization and neuronal degeneration in basal ganglia....Pages 85-88
Pathology associated with sporadic Parkinson’s disease — where does it end?....Pages 89-97
Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson’s disease....Pages 99-103
A short overview on the role of α-synuclein and proteasome in experimental models of Parkinson’s disease....Pages 105-109
The role of protein aggregates in neuronal pathology: guilty, innocent, or just trying to help?....Pages 111-117
New face of neuromelanin....Pages 119-123
The effect of neuromelanin on the proteasome activity in human dopaminergic SH-SY5Y cells....Pages 125-132
Potential sources of increased iron in the substantia nigra of parkinsonian patients....Pages 133-142
Iron and Friedreich ataxia....Pages 143-146
Nongenetic causes of Parkinson’s disease....Pages 147-151
Is atypical parkinsonism in the Caribbean caused by the consumption of Annonacae?....Pages 153-157
CYP450, genetics and Parkinson’s disease: gene × environment interactions hold the key....Pages 159-165
Unique cytochromes P450 in human brain: implication in disease pathogenesis....Pages 167-171
Cytochrome P450 and Parkinson’s disease: protective role of neuronal CYP 2E1 from MPTP toxicity....Pages 173-176
Nicotine induces brain CYP enzymes: relevance to Parkinson’s disease....Pages 177-180
Genetic causes of Parkinson’s disease: extending the pathway....Pages 181-189
Progress in familial Parkinson’s disease....Pages 191-204
Molecular mechanisms of nigral neurodegeneration in Park2 and regulation of parkin protein by other proteins....Pages 205-208
Parkin and defective ubiquitination in Parkinson’s disease....Pages 209-213
PINK-1 and DJ-1 — new genes for autosomal recessive Parkinson’s disease....Pages 215-219
Clinical and pathologic features of families with LRRK2 -associated Parkinson’s disease....Pages 221-229
Molecular genetic findings in LRRK2 American, Canadian and German families....Pages 231-234
Genetic and DAT imaging studies of familial parkinsonism in a Taiwanese cohort....Pages 235-240
Neuroimaging in Parkinson’s disease....Pages 241-248
Transcranial sonography in the early and differential diagnosis of Parkinson’s disease....Pages 249-254
How to judge animal models of Parkinson’s disease in terms of neuroprotection....Pages 255-260
Limitations of cellular models in Parkinson’s disease research....Pages 261-268
The Rotenone model of Parkinsonism — the five years inspection....Pages 269-272
Controversies on new animal models of Parkinson’s disease Pro and Con: the rotenone model of Parkinson’s disease (PD)....Pages 272-276
Proposed animal model of severe Parkinson’s disease: neonatal 6-hydroxydopamine lesion of dopaminergic innervation of striatum....Pages 277-279
α-Synuclein overexpression model....Pages 281-284
Kynurenines, Parkinson’s disease and other neurodegenerative disorders: preclinical and clinical studies....Pages 285-304
What’s new? Clinical progression and staging of Parkinson’s disease....Pages 305-308
Parkinson’s disease: premotor clinico-pathological correlations....Pages 309-319
Detection of preclinical Parkinson’s disease along the olfactory trac(t)....Pages 321-325
The clinical approach to gait disturbances in Parkinson’s disease; maintaining independent mobility....Pages 327-332
Getting around and communicating with the environment: visual cognition and language in Parkinson’s disease....Pages 333-338
Cardiovascular aspects of Parkinson disease....Pages 339-342
Multiple system atrophy and autonomic failure....Pages 343-347
Sleep disturbances and excessive daytime sleepiness in Parkinson disease: an overview....Pages 349-355
Sleep and wakefulness disturbances in Parkinson’s disease....Pages 357-360
Parkinson’s disease dementia: what’s in a Lewy body?....Pages 361-365
Role of microglia in inflammation-mediated degeneration of dopaminergic neurons: neuroprotective effect of Interleukin 10....Pages 367-371
Role of cytokines in inflammatory process in Parkinson’s disease....Pages 373-381
Surgical therapy for Parkinson’s disease....Pages 383-392
Deep brain stimulation for the treatment of Parkinson’s disease....Pages 393-399
Deep brain stimulation in Parkinson’s disease patients: biochemical evidence....Pages 401-408
Neurosurgery in Parkinson’s disease: the doctor is happy, the patient less so?....Pages 409-414
Placebo effect and dopamine release....Pages 415-418
A new look at levodopa based on the ELLDOPA study....Pages 419-426
Thirty five years of experience in the treatment of Parkinson’s disease with levodopa and associations....Pages 427-431
Concerning neuroprotective therapy for Parkinson’s disease....Pages 433-437
Triggering endogenous neuroprotective mechanisms in Parkinson’s disease: studies with a cellular model....Pages 439-442
Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression....Pages 443-446
M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson’s disease....Pages 447-456
Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety....Pages 457-465
Anti-apoptotic gene therapy in Parkinson’s disease....Pages 467-476
The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors....Pages 477-484
Pathophysiology of dystonia....Pages 485-488
Genetics of dystonia....Pages 489-495
Back Matter....Pages 497-506